Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb
BRIEF-Tempus Expands Strategic Collaboration With Bristol Myers Squibb Oct 23 (Reuters) - Tempus AI, Inc. TEM.O:
EXPANDS STRATEGIC COLLABORATION WITH BRISTOL MYERS SQUIBB
BMS WILL LICENSE MULTIMODAL ONCOLOGY DATA FROM CO THROUGH 2031 TO SUPPORT BIOLOGICAL & CLINICAL INSIGHT IDENTIFICATION
UNDER COLLABORATION BMS WILL GAIN ACCESS TO CO'S LENS PLATFORM, AN AI-FIRST, AGENTIC PLATFORM FOR ONCOLOGY DRUG DEVELOPMENT
Source text: ID:nBw438L4Pa
Further company coverage: TEM.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb